Publications
166
Citations
2,772
Est. group size
~9
Recurring co-author estimate
Active years
29
Publishing since 1998
Bhavana Konda's research focuses on clinical trials and treatment strategies for neuroendocrine tumors, including gastroenteropancreatic and pancreatic neuroendocrine tumors, as well as thyroid cancer. Work spans testing new drug combinations (such as cabozantinib, selpercatinib, and radioligand therapies like 177Lu-Dotatate), evaluating treatment safety and quality-of-life outcomes, and identifying biomarkers to guide therapy decisions. Much of this research involves multi-center phase I-III clinical trials conducted through cooperative oncology groups.
Publication output has grown substantially over the last decade, rising from single digits annually before 2020 to over 30 papers per year in 2023-2024, indicating an active and expanding research output.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- ETCTN 10558: A Phase II Randomized Control Trial of Triapine Plus Lutetium 177 Dotatate Versus Lutetium 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors
Endocrine Abstracts · 2026
- NET RETREAT: a CCTG-SWOG Phase II Study of 177Lutetium-Dotatate Retreatment vs. Standard of Care in Metastatic GEPNET Patients
Endocrine Abstracts · 2026
- Phase 2 study of cabozantinib (XL184) with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN10315)
The Oncologist · 2026
- Efficacy and safety of cabozantinib (CABO) in advanced neuroendocrine tumors (NET) according to hormone functional status: Subgroup analysis of phase 3 CABINET trial (Alliance A021602).
Journal of Clinical Oncology · 2026
- Bronchoscopic photodynamic therapy for endobronchial metastatic papillary thyroid carcinoma causing lobar airway obstruction: a case report
Annals of Translational Medicine · 2026
- Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement
The Lancet Diabetes & Endocrinology · 2025
- Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort
Journal for ImmunoTherapy of Cancer · 2025
- 1709MO Multi-center NCI-sponsored phase I study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
Annals of Oncology · 2025
- Appendiceal Neuroendocrine Tumors: Prognostic Role of Mesoappendiceal Invasion and Implications for Recommending Right Hemicolectomy versus Simple Appendectomy
Annals of Surgical Oncology · 2025
- Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET, Alliance A021602).
Journal of Clinical Oncology · 2025
- Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms
Endocrine Related Cancer · 2025
- Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE
Endocrine Oncology · 2025
- Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
UNC Libraries · 2025
- Risk of Neuroendocrine Neoplasms with Glucagon-Like-Petide-1 Receptor Agonist Use in Patients with Type 2 Diabetes Mellitus
medRxiv · 2025
- S790 Risk of Neuroendocrine Neoplasms With Glucagon-Like-Petide-1 Receptor Agonist Use in Patients With Type 2 Diabetes Mellitus
The American Journal of Gastroenterology · 2025
- Journal of Clinical Oncology×19
- Endocrine Abstracts×9
- Annals of Oncology×7
- The Journal of Clinical Endocrinology & Metabolism×5
- Journal of the National Comprehensive Cancer Network×5
- Manisha H. Shah
Medicine · The Ohio State University
- Ashima Goyal
Medicine · The Ohio State University
- Dramane Konate
Medicine · The Ohio State University
- Vineeth Sukrithan
Medicine · The Ohio State University
- Ye Zhou
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile